MedPath

Beijing Chest Hospital, Capital Medical University

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Phase 2
Recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2024-06-21
Last Posted Date
2024-12-16
Lead Sponsor
Beijing Chest Hospital, Capital Medical University
Target Recruit Count
35
Registration Number
NCT06467617
Locations
🇨🇳

Beijing Chest Hospital, Beijing, Beijing, China

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Phase 2
Not yet recruiting
Conditions
Limited-stage Small-cell Lung Cancer
Interventions
First Posted Date
2024-04-19
Last Posted Date
2024-04-19
Lead Sponsor
Beijing Chest Hospital, Capital Medical University
Target Recruit Count
60
Registration Number
NCT06375109

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.